Table 3.
Mobility (step count) in LOPD subjects relative to the general population and chronic disease patients
| Study | Population | Analyses sample | Study design | Wearable device | Descriptive statistics |
|---|---|---|---|---|---|
| Free-Living Mobility Assessment Using Wearable Technology in U.S. Adults with Late-Onset Pompe Disease (Current manuscript prepared by Sanofi Genzyme and PatientsLikeMe) |
US patients (≥18 years) with late-onset Pompe disease • Age (mean): 43 years • Sex: 90% female • Race: 86% white Excluded patients who were bedridden, required a wheelchair all day, or required invasive ventilation |
29 patients | Observational study with continuous remote monitoring physical activity (at home) for 6–8 weeks | Fitbit One™ pedometer (3-axis accelerometer that clips onto an individual’s belt, pocket, or bra) | Mean: 3145 steps per day (range: 722–6304) |
| Pedometer-Measured Physical Activity and Health Behaviors in United States Adults9 |
US general population (≥18 years) • Age (mean): 46 years • Sex: 54% female • Race: 89% white Only adult cohort with valid data reported for analyses |
1136 respondents | Observational study data collected over a 2-day period (at home) | Accusplit AE120 pedometer (worn on the belt or waistband during all waking hours) | Mean: 5117 steps per day |
| Promoting physical activity in COPD: insights from a randomized trial of a web-based intervention and pedometer use12 |
US Veterans with COPD (≥40 years) • Age (mean): 69 years • Sex: 1.5% female • Race: 92% White Population age ≥40 years with ≥10 pack-year smoking history |
109 patients (intervention arm, n = 57; control arm, n = 52) | Randomized control trial with an intervention arm (web-based intervention plus pedometer) and control arm (pedometer only) for 3 months | Omron HJ-720 ITC pedometer (worn during all waking hours) |
Baseline data Mean: 3445 steps per day (intervention arm: 3149; control arm 3770) 7 days baseline data reported as it is more likely to be comparable to free living behavior |
| Use of pedometer and Internet-mediated walking program in patients with chronic obstructive pulmonary disease10 |
US patients with COPD (≥40 years) • Age (mean): 56 years • Sex: 46% female • Race: 75% white Population age ≥40 years, self-reporting emphysema, asthma, bronchitis and current/former smokers |
24 patients | Randomized control trial to test an Internet-mediated walking program for 16 weeks (comparator arm included patients without COPD) | Omron HJ-720 ITC pedometer (worn during all waking hours) |
Baseline data Mean: 3429 steps per day (range: 642–7166) 7 days baseline data reported as it is more likely to be comparable to free living behavior |
| Continuous daily assessment of multiple sclerosis disability using remote step count monitoring11 |
US Patients (≥18 years) with multiple sclerosis • Age (mean): 50 years • Sex: 64% female population included relapsing or progressive type who could walk unaided for ≥2 min |
99 patients (38 progressive; 61 relapsing) | Observational study with continuous remote monitoring (at home) for 4 weeks | Fitbit Flex™ pedometer (3-axis accelerometer that was worn as a wrist bracelet on the non-dominant wrist) |
Mean: 5478 steps per day (range: 533–18,649) |
| Free-Living Physical Activity Monitoring in Adult U.S. Patients with Multiple Sclerosis using a Consumer Wearable Device13 |
US patients (≥18 years) with multiple sclerosis • Age (mean): 52 years • Sex: 75% female Excluded patients who required a wheelchair for most of their daily activities Analyses were conducted in patients with complete data on all covariates and at least 7 days of wearable device data |
114 patients | Observational study remote monitoring physical activity (at home) for 3–4 weeks | Fitbit One™ pedometer (3-axis accelerometer that clips onto an individual’s belt, pocket, or bra) | Mean: 4393 steps per day |
COPD chronic obstructive pulmonary disease, MS multiple sclerosis